This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Asahi Kasei Corporation
Drug Names(s): Flivas (Korea)
Description: Naftopidil (Flivas) is a selective 1-adrenergic receptor antagonist or alpha blocker. Naftopidil (Flivas) is also an antihypertensive agent and binds specifically to alpha 1-adrenoceptors. Naftopidil relaxes aortic strips precontracted with norepinephrine concentration-dependently, and naftopidil (Flivas) shifts the concentration-response curve of norepinephrine in a parallel manner to the right.
Deal Structure: In April 2009, Asahi Kasei Pharma and Dong-A concluded a license agreement granting Dong-A exclusive rights for the development and sale of Flivas in Korea. Dong-A obtained approval from the Korea Food and Drug Administration (KFDA) as an agent for the treatment of BPH in April 2011.
Partners: Dong Wha Pharmaceutical Ind. Co.
Additional information available to subscribers only: